Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

TP53 mutation occurs in 50–75% of human pancreatic ductal adenocarcinomas (PDAC) following an initiating activating mutation in the KRAS gene. These p53 mutations frequently result in expression of a stable protein, p53R175H, rather than complete loss of protein expression. In this study we elucidate the functions of mutant p53 (Trp53R172H), compared to knockout p53 (Trp53fl), in a mouse model of PDAC. First we find that although KrasG12D is one of the major oncogenic drivers of PDAC, most KrasG12D-expressing pancreatic cells are selectively lost from the tissue, and those that remain form premalignant lesions. Loss, or mutation, of Trp53 allows retention of the KrasG12D-expressing cells and drives rapid progression of these premalignant lesions to PDAC. This progression is consistent with failed growth arrest and/or senescence of premalignant lesions, since a mutant of p53, p53R172P, which can still induce p21 and cell cycle arrest, is resistant to PDAC formation. Second, we find that despite similar kinetics of primary tumor formation, mutant p53R172H, as compared with genetic loss of p53, specifically promotes metastasis. Moreover, only mutant p53R172H-expressing tumor cells exhibit invasive activity in an in vitro assay. Importantly, in human PDAC, p53 accumulation significantly correlates with lymph node metastasis. In summary, by using ‘knock-in’ mutations of Trp53 we have identified two critical acquired functions of a stably expressed mutant form of p53 that drive PDAC; first, an escape from KrasG12D-induced senescence/growth arrest and second, the promotion of metastasis.

[1]  Jonathan Melamed,et al.  Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence , 2008, Cell.

[2]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[3]  D. Klimstra,et al.  Trp53 deletion stimulates the formation of metastatic pancreatic tumors. , 2008, The American journal of pathology.

[4]  H. Pang,et al.  DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model , 2007, The Journal of experimental medicine.

[5]  A. Multani,et al.  Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53‐dependent cellular senescence , 2007, EMBO reports.

[6]  M. Korc,et al.  The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia , 2007, Proceedings of the National Academy of Sciences.

[7]  Z. Ju,et al.  p21 delays tumor onset by preservation of chromosomal stability , 2006, Proceedings of the National Academy of Sciences.

[8]  Julie A. Wilkins,et al.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo , 2006, Proceedings of the National Academy of Sciences.

[9]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[10]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[11]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[12]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[13]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[14]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[15]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[16]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[17]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[18]  H. Varmus,et al.  The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer. , 2003, Genes & development.

[19]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[20]  J. Cameron,et al.  Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray , 2003, Modern Pathology.

[21]  D. Longnecker,et al.  Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. , 2003, Cancer research.

[22]  D. Melton,et al.  Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. , 2002, Development.

[23]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[24]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[25]  Caiying Guo,et al.  Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon cre‐mediated excision , 2000, Genesis.

[26]  R H Hruban,et al.  Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  T. Soussi.  The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation , 2000, Annals of the New York Academy of Sciences.

[28]  E. Hunziker,et al.  Nestin-expressing cells in the pancreatic islets of Langerhans. , 2000, Biochemical and biophysical research communications.

[29]  D. Medina,et al.  Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis , 1998, Oncogene.

[30]  H. Koeffler,et al.  p21WAF1 mutations and human malignancies. , 1997, Leukemia & lymphoma.

[31]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[32]  K. Vousden,et al.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.

[33]  L. Chin,et al.  Role of the INK4a Locus in Tumor Suppression and Cell Mortality , 1996, Cell.

[34]  B. Ozanne,et al.  Fos-transformation activates genes associated with invasion. , 1994, Oncogene.

[35]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[36]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[37]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[38]  S. Hirohashi,et al.  Pancreatic adenocarcinomas frequently show p53 gene mutations. , 1993, The American journal of pathology.

[39]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[40]  S. Matsuno,et al.  Clinicopathological study on hematogenous metastasis of pancreatic cancer , 1986, The Japanese journal of surgery.

[41]  A. Multani,et al.  Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.

[42]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.